GKIM
BIIB icon

GW&K Investment Management’s Biogen BIIB Stock Holding History

GW&K Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49K Sell
229
-10
-4% -$1.91K ﹤0.01% 597
2026
Q1 		$44K Hold
239
– – ﹤0.01% 583
2025
Q4 		$42K Hold
239
– – ﹤0.01% 584
2025
Q3 		$33K Sell
239
-21
-8% -$2.84K ﹤0.01% 617
2025
Q2 		$33K Buy
260
+168
+183% +$20.9K ﹤0.01% 582
2025
Q1 		$13K Sell
92
-20
-18% -$2.86K ﹤0.01% 737
2024
Q4 		$17K Buy
112
+59
+111% +$9.95K ﹤0.01% 656
2024
Q3 		$10K Buy
53
+3
+6% +$628 ﹤0.01% 772
2024
Q2 		$12K Sell
50
-4
-7% -$869 ﹤0.01% 670
2024
Q1 		$12K Buy
54
+4
+8% +$937 ﹤0.01% 640
2023
Q4 		$13K Buy
50
+1
+2% +$246 ﹤0.01% 595
2023
Q3 		$13K Sell
49
-5
-9% -$1.34K ﹤0.01% 548
2023
Q2 		$15K Buy
+54
New +$16.1K ﹤0.01% 510
2022
Q3 		– Sell
-18
Closed -$4K – 448
2022
Q2 		$4K Sell
18
-12
-40% -$2.45K ﹤0.01% 626
2022
Q1 		$6K Buy
+30
New +$6.52K ﹤0.01% 496

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GW&K Investment Management's BIIB Position: Q2 2026 in Review

GW&K Investment Management reduced its Biogen (BIIB) stake by 4.2% in Q2 2026, selling an estimated $1.91K and leaving 229 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #597.

GW&K Investment Management first reported a position in BIIB in Q1 2022 and has held it in 15 quarters since. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • GW&K Investment Management held 229 shares of Biogen worth $49K as of Q2 2026.
  • GW&K Investment Management sold 10 Biogen shares in Q2 2026, an estimated $1.91K.
  • Biogen made up ﹤0.01% of GW&K Investment Management's portfolio in Q2 2026, its #597 holding.
  • GW&K Investment Management first reported a position in Biogen in Q1 2022 and has held it in 15 quarters since.
  • 1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.